"Antibodies, Neutralizing" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antibodies that reduce or abolish some biological activity of a soluble antigen or infectious agent, usually a virus.
Descriptor ID |
D057134
|
MeSH Number(s) |
D12.776.124.486.485.114.244 D12.776.124.790.651.114.244 D12.776.377.715.548.114.244
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antibodies, Neutralizing".
Below are MeSH descriptors whose meaning is more specific than "Antibodies, Neutralizing".
This graph shows the total number of publications written about "Antibodies, Neutralizing" by people in this website by year, and whether "Antibodies, Neutralizing" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2009 | 1 | 0 | 1 |
2010 | 3 | 0 | 3 |
2011 | 3 | 5 | 8 |
2012 | 1 | 4 | 5 |
2013 | 0 | 4 | 4 |
2014 | 3 | 3 | 6 |
2015 | 3 | 4 | 7 |
2016 | 2 | 0 | 2 |
2017 | 1 | 0 | 1 |
2018 | 3 | 1 | 4 |
2019 | 2 | 4 | 6 |
2020 | 1 | 5 | 6 |
2021 | 4 | 8 | 12 |
2022 | 0 | 2 | 2 |
2023 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antibodies, Neutralizing" by people in Profiles.
-
Immunogenicity of the BA.1 and BA.4/BA.5 Severe Acute Respiratory Syndrome Coronavirus 2 Bivalent Boosts: Preliminary Results From the COVAIL Randomized Clinical Trial. Clin Infect Dis. 2023 08 22; 77(4):560-564.
-
Transfusion-Transmitted Cache Valley Virus Infection in a Kidney Transplant Recipient With Meningoencephalitis. Clin Infect Dis. 2023 02 08; 76(3):e1320-e1327.
-
COVID-19 symptom severity predicts neutralizing antibody activity in a community-based serological study. Sci Rep. 2022 07 18; 12(1):12269.
-
Teach 'em young: Influenza vaccines induce broadly neutralizing antibodies in children. Cell Rep Med. 2022 02 15; 3(2):100531.
-
Real-World Experience of Bamlanivimab for Coronavirus Disease 2019 (COVID-19): A Case-Control Study. Clin Infect Dis. 2022 01 07; 74(1):24-31.
-
Broadly neutralizing antibodies target a haemagglutinin anchor epitope. Nature. 2022 02; 602(7896):314-320.
-
Next-Generation Serology by Mass Spectrometry: Readout of the SARS-CoV-2 Antibody Repertoire. J Proteome Res. 2022 01 07; 21(1):274-288.
-
Monoclonal antibody treatment for COVID-19 in solid organ transplant recipients. Transpl Infect Dis. 2022 Feb; 24(1):e13759.
-
A Multifunctional Neutralizing Antibody-Conjugated Nanoparticle Inhibits and Inactivates SARS-CoV-2. Adv Sci (Weinh). 2022 01; 9(2):e2103240.
-
Generation of potent cellular and humoral immunity against SARS-CoV-2 antigens via conjugation to a polymeric glyco-adjuvant. Biomaterials. 2021 11; 278:121159.